Is This the Right Time to Add PBH Stock to Your Portfolio?

Prestige Consumer Healthcare PBH continues to benefit from robust momentum, supported by the expansion of its brand portfolio through organic growth and acquisitions. Also, the company benefits from growing online adoption supported by broader brand reach despite retailer order-timing volatility. A stable solvency looks encouraging. However, unfavorable foreign exchange poses risks for Prestige Consumer’s operations and profitability. 

In the past year, this Zacks Rank #2 (Buy) stock has lost 20.8% compared with the industry’s 25% decline. The S&P 500 composite has increased 21.7% over the said time frame.

The renowned consumer healthcare product company has a market capitalization of $2.97 billion. Its earnings yield of 7.3% is well ahead of the industry’s 0.2% yield. PBH’s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average surprise of 1.8%.

Let’s delve deeper.

Upsides for PBH Stock

Acquisitions Aid Growth: Acquisitions of TheraTears, Hydralyte and Pillar5 have helped Prestige Consumer Healthcare expand its portfolio. In fiscal 2027, the company added two larger consumer-health platforms — the Breathe Right portfolio, acquired on June 12, 2026, and LaCorium Health, acquired on July 1, 2026.

Breathe Right is expected to contribute approximately $200 million to annual revenues, while LaCorium is anticipated to contribute roughly $40 million, together increasing Prestige’s revenue base by nearly 20%. For fiscal 2027, the acquisitions are expected to account for approximately $190 million of revenues, lifting reported revenue guidance to $1.29-$1.315 billion while organic growth guidance remains at 1-3%. 

Breathe Right was largely integrated within 60 days of closing, with consumer awareness exceeding 90%, distribution across more than 20 countries and additional product extensions including Menthol and Sport. LaCorium adds Dermal Therapy and other therapeutic skin care brands in Australia, with management targeting distributor optimization, sales integration and operating efficiencies over time. 

Breathe Right is still expected to deliver approximately $0.25 of annualized EPS accretion in a normalized environment, while management plans to advance the LaCorium integration over the remainder of fiscal 2027. These additions broaden Prestige’s category and geographic growth avenues. 

E-Commerce Strength: Prestige Consumer Healthcare continues to benefit from its long-term investment in digital channels and channel-agnostic distribution. E-commerce represented about 18% of net sales in fiscal 2026, up from low single digits in fiscal 2019. 

In the first quarter of fiscal 2027, e-commerce consumption again grew at a double-digit rate as consumers continued to seek value, broad assortment and price transparency online. Reported shipments were affected by retailer order timing, with roughly two percentage points of first-quarter growth pulled forward from the second quarter. Management still expects organic revenue growth for the first half. Continued consumer adoption of online purchasing supports brand reach even as quarterly retailer orders remain uneven. 

Stable Solvency, Elevated Leveraged: Prestige Consumer ended the fiscal first quarter of 2027 with cash and cash equivalents of $89.1 million and $10.5 million of short-term debt. Long-term debt was approximately $2.01 billion, while net debt was about $2.0 billion following the Breathe Right acquisition financing. Adjusted free cash flow reached $83.7 million in the quarter, and management now guides at least $270 million for fiscal 2027. 

Image Source: Zacks Investment Research

What Ails PBH Stock?

Currency Fluctuations: Prestige Consumer Healthcare relies on brokers and distributors for the sale of its products in foreign countries, with International OTC Healthcare representing about 16% of fiscal 2026 revenues. As a result, foreign exchange movements can create variability in reported results and influence pricing dynamics for products sourced from foreign third-party manufacturers. 

In the fourth quarter of fiscal 2026, revenues declined 5.0% year over year, while the organic decline excluding foreign currency was 6.4%, indicating that currency provided an offset. The company’s international exposure leaves results susceptible to swings that can complicate reported growth comparisons. 

PBH Stock Estimate Trend

In the past 30 days, the Zacks Consensus Estimate for PBH’s fiscal 2026 earnings per share has moved north 2% to $4.56.

The Zacks Consensus Estimate for the company’s fiscal 2026 revenues is pegged at $1.29 billion, suggesting an increase of 18.9% from the year-ago reported number.

Other Key Picks

Some other top-ranked stocks in the broader medical space are Globus Medical GMED, Veracyte VCYT and Illumina ILMN.

Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

Illumina, presently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% growth. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research